Rivaroxaban Pharmacokinetics/Pharmacodynamics (PK/PD) Study in Pediatric Subjects
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
The first study with rivaroxaban in pediatric subjects is a Phase I study, where the
pharmacokinetic/pharmacodynamic (PK/PD) profile of rivaroxaban will be investigated to
confirm that the exposure is comparable to adults. This study is a single dose study with
multiple PK/PD measurements in pediatric subjects at the end of their Venous Thromboembolism
(VTE) treatment.